Cure My Disease

Don't miss your cure!

 Log in / Sign up

A single blood draw to unmask hidden infections in immune-weakened patients?

NCT ID NCT06075888

Diagnosis Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests a new blood test that uses metagenomic sequencing to identify any infection-causing microbe in cancer patients who develop febrile neutropenia—a serious fever that occurs when their immune system is weakened by treatment. The test aims to find the culprit faster than standard methods, which could help doctors start the right treatment sooner. Researchers will compare the test's results with conventional lab tests to see how accurate it is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metagenomic sequencing test (DISQVER) on a blood sample
What this could lead to
If it works, this blood test could speed up infection detection in vulnerable cancer patients, allowing earlier treatment and better outcomes.
What could go wrong
The test is still being evaluated, and its accuracy compared to standard methods is unproven. It may not detect all pathogens or could give false results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

184 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient * Age ≥18 years * Being treated for solid tumour or haematological malignancy * Presenting with high-risk febrile neutropenia (high-risk is defined by a Multinational Association for Supportive Care in Cancer (MASCC) score ≥ 21) with an expected duration of neutropenia ≥ 7 days. Neutropenia is defined as an absolute neutrophil count ≤ 500/mm3. Fever is defined as temperature ≥ 38.3°C or ≥ 38°C twice within 1 hour. * Free, without guardianship, tutelage or subordination; * covered by a social security scheme or by a third party; * have given informed consent to participate in the study. Exclusion Criteria: * Antibiotic therapy in the 24 hours prior to enrolment, with the exception of prophylactic use of trimethoprim-sulfamethoxazole (Cotrimoxazole) and penicillin G (Oracillin®). * Previous study participation * Patients with enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons in a health or social care institution, adults under legal protection; * Pregnant or lactating women of childbearing age (menopause must be documented) who refuse or do not have an effective method of contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device or surgical: tubal ligation, hysterectomy, total oophorectomy) for the duration of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunodepressed patients (hemato-oncology) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis Fever Fungemia neutropenia Viremia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunodepressed patients (hemato-oncology)

Contacts and locations

Locations

  • C.H.U. d'Angers

    Angers, 49933, France

  • C.H.U. de Limoges

    Limoges, France

  • C.H.U. de Poitiers

    Poitiers, 86000, France

  • C.H.U. de Tours

    Tours, 37044, France

  • CHU de Brest

    Brest, 29606, France